The Library
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
Tools
Tools
Tools
Lipplaa, Astrid, Fernandes, Ricardo, Marshall, Andrea, Lorigan, Paul, Dunn, Janet A., Myers, Kevin A, Barker, Emily, Newton-Bishop, Julia, Middleton, Mark R. and Corrie, Pippa G. (2018) 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. British Journal of Cancer, 119 . pp. 793-800. doi:10.1038/s41416-018-0179-6
|
PDF
WRAP-25-hydroxyvitamin-D-serum-patients-high-risk-Marshall-2018.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (373Kb) | Preview |
Official URL: http://doi.org/10.1038/s41416-018-0179-6
Abstract
Background
Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identi fi ed an inverse correlation with Breslow thickness, but an inconsistent impact on survival. Vitamin D in later stages of melanoma has been less studied.
Methods
Vitamin D was measured in serum from 341 patients with resected stage IIB – IIIC melanoma recruited to the AVAST-M adjuvant melanoma randomised trial, collected prior to randomisation, then at 3 and 12 months. Vitamin D levels were compared with patient demographics, known melanoma prognostic factors, disease-free interval (DFI) and overall survival (OS).
Results
A total of 73% patients had stage III melanoma, 32% were enroled (and therefore tested) >1 year after primary melanoma diagnosis. Median pre-randomisation vitamin D level was 56.5 (range 12.6 – 189.0 nmol/L). Vitamin D levels did not signi fi cantly vary over 12 months ( p = 0.24). Individual pre-randomisation vitamin D levels did not differ signi fi cantly for Breslow thickness, tumour ulceration, or disease stage. Neither did pre-randomisation vitamin D predict for DFI (HR = 0.98 per 10 nmol/L increase; 95% con fi dence interval (CI) 0.93 – 1.04, p = 0.59) or OS (HR = 0.96 per 10 nmol/L increase, 95% CI 0.90 – 1.03, p = 0.31). For stage II patients, DFI improved with higher pre-randomisation vitamin D levels for those on bevacizumab (HR = 0.74 per 10 nmol nmol/L increase; 95% CI 0.56 – 0.97), but not for the observation arm (HR = 1.07 per 10 nmol/L increase; 95% CI 0.85 – 1.34).
Conclusions
In this stage II/III melanoma cohort, vitamin D did not correlate with known prognostic markers, nor predict for DFI or OS, but there was some evidence of bene fi t for patients with stage II disease treated with bevacizumab
| Item Type: | Journal Article | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | |||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
|||||||||
| SWORD Depositor: | Library Publications Router | |||||||||
| Library of Congress Subject Headings (LCSH): | Bevacizumab, Melanoma, Clinical trials | |||||||||
| Journal or Publication Title: | British Journal of Cancer | |||||||||
| Publisher: | Nature Publishing Group | |||||||||
| ISSN: | 0007-0920 | |||||||||
| Official Date: | 2 October 2018 | |||||||||
| Dates: |
|
|||||||||
| Date of first compliant deposit: | 9 August 2018 | |||||||||
| Volume: | 119 | |||||||||
| Page Range: | pp. 793-800 | |||||||||
| DOI: | 10.1038/s41416-018-0179-6 | |||||||||
| Status: | Peer Reviewed | |||||||||
| Publication Status: | Published | |||||||||
| Access rights to Published version: | Open Access | |||||||||
| Copyright Holders: | The Author(s) | |||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
